April 2026 in “Cosmetics” In this randomized, double-blind, placebo-controlled trial, researchers found that a multi-targeted cosmetic formulation containing TrinogeniX™ significantly increased hair density and thickness in individuals with androgenetic alopecia without adverse effects, suggesting it as a potential safe and effective treatment option.
January 2025 in “Dermatologic Therapy” In this review, researchers explored key mechanisms underlying androgenetic alopecia, revealing how hormonal, oxidative, inflammatory, and lipid dysregulation suppress hair growth pathways and suggesting new therapeutic targets such as DP2 antagonists and microbiome modulators.
October 2022 in “The Korean Journal of Physiology and Pharmacology” This review discusses the roles of prostaglandins in hair loss and highlights their potential as targets for new alopecia treatments, but reports no new clinical findings.
18 citations
,
February 2018 in “International Journal of Molecular Sciences” This study found that prostaglandin D2 promotes androgen receptor and AKT signaling in human dermal papilla cells through the DP2 receptor, potentially contributing to androgenetic alopecia.
9 citations
,
December 2020 in “Dermatologic Therapy” This review found that oral and topical phosphodiesterase inhibitors and topical prostaglandin analogues are safe and effective treatments for various skin diseases, including psoriasis, atopic dermatitis, vitiligo, and alopecia.